Tiziana Life Sciences LtdNASDAQ:TLSANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.9900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.9000/ 19
- Ask / Lots1.0000/ 8
- Open / Previous Close0.9900 / 0.9900
- Day Range
- 52 Week Range
- Volume170,146
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 5396 | 0.9901 |
| 09:34 ET | 1000 | 0.9949 |
| 09:38 ET | 100 | 0.99 |
| 09:39 ET | 1000 | 0.9901 |
| 09:41 ET | 7547 | 0.95 |
| 09:43 ET | 3132 | 0.9254 |
| 09:45 ET | 200 | 0.932 |
| 09:48 ET | 900 | 0.9255 |
| 09:50 ET | 100 | 0.93 |
| 09:54 ET | 1000 | 0.950101 |
| 09:56 ET | 200 | 0.95 |
| 09:57 ET | 100 | 0.95 |
| 09:59 ET | 100 | 0.95 |
| 10:06 ET | 800 | 0.9501 |
| 10:10 ET | 200 | 0.965 |
| 10:12 ET | 436 | 0.98 |
| 10:14 ET | 320 | 0.97 |
| 10:15 ET | 1071 | 0.9527 |
| 10:26 ET | 400 | 0.9527 |
| 10:30 ET | 249 | 0.95 |
| 10:32 ET | 785 | 0.9625 |
| 10:39 ET | 10000 | 0.98 |
| 10:44 ET | 1300 | 0.9899 |
| 10:50 ET | 5093 | 0.9899 |
| 10:51 ET | 400 | 0.99 |
| 10:55 ET | 1571 | 0.99 |
| 10:57 ET | 9804 | 0.994999 |
| 11:00 ET | 2753 | 1.02 |
| 11:02 ET | 1900 | 1.03 |
| 11:04 ET | 15049 | 0.9552 |
| 11:08 ET | 714 | 0.9978 |
| 11:09 ET | 490 | 0.9977 |
| 11:11 ET | 1285 | 1.03 |
| 11:13 ET | 1400 | 0.9977 |
| 11:15 ET | 4803 | 1.04 |
| 11:18 ET | 5500 | 1.07 |
| 11:20 ET | 1403 | 1.05 |
| 11:22 ET | 3889 | 1.01 |
| 11:26 ET | 200 | 1.04 |
| 11:27 ET | 1000 | 1.03 |
| 11:29 ET | 1738 | 1.0109 |
| 11:36 ET | 4500 | 1.01 |
| 11:38 ET | 500 | 1.0075 |
| 11:40 ET | 755 | 1.005 |
| 11:42 ET | 785 | 1.0002 |
| 11:44 ET | 100 | 1.005 |
| 11:47 ET | 400 | 1.005 |
| 11:54 ET | 400 | 1.005 |
| 12:00 ET | 2532 | 1.005 |
| 12:02 ET | 4200 | 0.9988 |
| 12:05 ET | 1242 | 0.9719 |
| 12:09 ET | 115 | 0.95 |
| 12:12 ET | 1995 | 0.95 |
| 12:16 ET | 1000 | 0.975 |
| 12:23 ET | 100 | 1 |
| 12:25 ET | 100 | 0.95 |
| 12:30 ET | 2100 | 0.9634 |
| 12:32 ET | 1039 | 0.9634 |
| 12:41 ET | 177 | 0.98 |
| 12:43 ET | 104 | 0.97 |
| 01:10 ET | 817 | 0.975 |
| 01:14 ET | 153 | 0.9702 |
| 01:19 ET | 3289 | 0.9851 |
| 01:28 ET | 100 | 0.99 |
| 01:30 ET | 6100 | 0.98 |
| 01:35 ET | 1000 | 0.9873 |
| 01:46 ET | 100 | 0.99 |
| 02:02 ET | 100 | 0.99 |
| 02:06 ET | 750 | 1 |
| 02:08 ET | 192 | 0.99505 |
| 02:09 ET | 769 | 1 |
| 02:15 ET | 4523 | 0.985 |
| 02:20 ET | 5000 | 0.9898 |
| 02:31 ET | 2300 | 0.9702 |
| 02:44 ET | 500 | 0.99 |
| 02:58 ET | 100 | 0.98 |
| 03:07 ET | 292 | 0.98 |
| 03:14 ET | 476 | 0.97 |
| 03:18 ET | 3384 | 0.9889 |
| 03:20 ET | 100 | 0.99 |
| 03:23 ET | 3030 | 0.9899 |
| 03:25 ET | 1500 | 0.99 |
| 03:27 ET | 2500 | 0.99 |
| 03:30 ET | 231 | 0.99 |
| 03:38 ET | 272 | 0.99 |
| 03:45 ET | 1317 | 0.99 |
| 03:54 ET | 126 | 0.99 |
| 03:56 ET | 3430 | 0.9701 |
| 03:59 ET | 465 | 0.99 |
Jul 24, 2024
Tiziana Life Sciences Granted FDA Fast Track Designation, from 7:00AM ET on Wednesday Jul 24, 2024 by Dow Jones
7:00AM ET on Wednesday Jul 24, 2024 by Dow Jones
Jun 28, 2024
Tiziana Receives $3.4 Million in Non-Dilutive Funding, from 11:01AM ET on Friday Jun 28, 2024 by Dow Jones
11:01AM ET on Friday Jun 28, 2024 by Dow JonesPress Release: Tiziana Receives $3.4 Million in Non-Dilutive Funding, from 11:01AM ET on Friday Jun 28, 2024 by Dow Jones
11:01AM ET on Friday Jun 28, 2024 by Dow Jones
Jun 26, 2024
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab, from 7:00AM ET on Wednesday Jun 26, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 102.1M | -6.6x | --- |
Checkpoint Therapeutics Inc | 98.2M | -1.1x | --- |
InflaRx NV | 90.1M | -2.0x | --- |
RAPT Therapeutics Inc | 108.6M | -1.1x | --- |
Cardiff Oncology Inc | 105.8M | -2.6x | --- |
Hillevax Inc | 93.0M | -0.6x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer, Chief Scientific Officer, Executive Director
- Kunwar Shailubhai
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $102.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 103.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-0.15 |
Book Value | $0.19 |
P/E Ratio | -6.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
